Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H2 2018

  • ID: 4590350
  • Report
  • 71 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Biogen Inc
  • BioMAS Ltd
  • Daiichi Sankyo Co Ltd
  • EA Pharma Co Ltd
  • Immunwork Inc
  • Morphic Therapeutic Inc
  • MORE
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H2 2018

Summary:

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) pipeline Target constitutes close to 10 molecules. The latest report Integrin Alpha 4 - Pipeline Review, H2 2018, outlays comprehensive information on the Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Integrin Alpha 4 is a protein encoded by ITGA4. Integrins alpha-4 (VLA-4) subunit associates with a beta 1 or beta-7 subunit to form an integrin that plays a role in cell motility and migration. This integrin is a therapeutic target for the treatment of multiple sclerosis, Crohn's disease and inflammatory bowel disease. They are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1.

The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 3, 3 and 2 respectively. Report covers products from therapy areas Gastrointestinal, Central Nervous System, Immunology, Infectious Disease, Oncology, Cardiovascular, Genetic Disorders, Ophthalmology and Respiratory which include indications Graft Versus Host Disease (GVHD), Inflammatory Bowel Disease, Ulcerative Colitis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Age Related Macular Degeneration, Asthma, Autoimmune Disorders, Celiac Disease, Crohn's Disease (Regional Enteritis), Duchenne Muscular Dystrophy, Epilepsy, Genital Warts (Condylomata Acuminata), Human Immunodeficiency Virus (HIV) Infections (AIDS), Multiple Sclerosis, Paraneoplastic Syndrome, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS) and Ventricular Septal Defect.

Furthermore, this report also reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)
  • The report reviews Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Biogen Inc
  • BioMAS Ltd
  • Daiichi Sankyo Co Ltd
  • EA Pharma Co Ltd
  • Immunwork Inc
  • Morphic Therapeutic Inc
  • MORE
Introduction

Report Coverage

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Overview

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Companies Involved in Therapeutics Development

Antisense Therapeutics Ltd

Biogen Inc

BioMAS Ltd

Daiichi Sankyo Co Ltd

EA Pharma Co Ltd

Immunwork Inc

Morphic Therapeutic Inc

Takeda Pharmaceutical Co Ltd

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Drug Profiles

AS-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATL-1102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

carotegrast - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ET-3764 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

natalizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize VLA-4 for Asthma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Integrin Alpha 4 and Beta 2 for Autoimmune Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TE-5232 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vedolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Dormant Products

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Discontinued Products

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Product Development Milestones

Featured News & Press Releases

Jul 02, 2018 : Takeda Obtains New Drug Application Approval for Entyvio (vedolizumab) for the Treatment of Ulcerative Colitis in Japan

Jun 05, 2018 : Analysis of real-world safety data shows gut-selective ENTYVIO (vedolizumab) had fewer serious infections and adverse events than those on systemic TNFa-antagonist therapy in ulcerative colitis and Crohn's disease patients

Jun 03, 2018 : Takeda Highlights Favorable Safety Profile of Entyvio (vedolizumab) Through Comparative Real-World Data Versus TNFa-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease

May 15, 2018 : Bio-Rad Introduces Anti-Vedolizumab Antibodies

Feb 28, 2018 : Approval received for Phase II trial of ATL1102 in Duchenne Muscular Dystrophy

Feb 16, 2018 : Entyvio (vedolizumab) Shows Higher Rates of Mucosal Healing Versus TNFa-Antagonist Therapy in Ulcerative Colitis and Crohn’s Disease Patients in Comparative Effectiveness Real-World Data Analysis

Feb 07, 2018 : Biogen Reports Top-Line Results from Phase 2b Study of Natalizumab in Acute Ischemic Stroke

Feb 06, 2018 : Takeda Announces Publication of Study Utilizing State-of-the-Art Modeling to Better Understand Optimal Treatment Positioning for Patients with Ulcerative Colitis

Dec 07, 2017: Cassiopea Announces Completion of Recruitment of Phase II Proof of Concept Trial of CB-06-02 Trial in Genital Warts

Nov 21, 2017: ATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy Status Update

Nov 09, 2017: New Post-Hoc Analysis Evaluating Deep Remission with Entyvio (vedolizumab) in Patients with Moderately to Severely Active Ulcerative Colitis Recognized as "Poster of Distinction" at AIBD 2017 Annual Conferenc

Nov 01, 2017: Meta-Analysis Using Real-World Data Evaluates Safety Profile of Entyvio (vedolizumab) in Patients with Moderate to Severe Ulcerative Colitis or Crohn’s Disease

Oct 30, 2017: ATL1102 'Black Hole' MS data presented at the 7th Joint ECTRIMS-ACTRIMS Meeting

Oct 17, 2017: ATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy Update

Oct 16, 2017: New Post-Hoc Analyses Report Early Symptomatic Improvement in Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Patients Taking Entyvio (vedolizumab), Particularly in Biologic-Naïve Patients

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Antisense Therapeutics Ltd, H2 2018

Pipeline by Biogen Inc, H2 2018

Pipeline by BioMAS Ltd, H2 2018

Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Pipeline by EA Pharma Co Ltd, H2 2018

Pipeline by Immunwork Inc, H2 2018

Pipeline by Morphic Therapeutic Inc, H2 2018

Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Dormant Products, H2 2018 (Contd..2), H2 2018

Discontinued Products, H2 2018

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Antisense Therapeutics Ltd
  • Biogen Inc
  • BioMAS Ltd
  • Daiichi Sankyo Co Ltd
  • EA Pharma Co Ltd
  • Immunwork Inc
  • Morphic Therapeutic Inc
  • Takeda Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll